Veritas In Silico

Veritas In Silico is a Tokyo-based AI drug discovery company specializing in small molecule drugs that target RNA. Using its proprietary AI platform and the AISLAR screening methodology, the company identifies and designs small molecules capable of binding to mRNA structures, enabling novel therapeutic approaches for cancer, genetic diseases, and other conditions. Listed on the Tokyo Stock Exchange Growth Market in February 2024, Veritas In Silico has established co-discovery partnerships with major pharmaceutical companies including Takeda, Shionogi, Toray, Asahi Kasei Pharma, and Mitsubishi Gas Chemical.